Rapid Autopsy in Melanoma Consortium

This collection will bring together genomic data from multiple projects involving an international consortium of rapid autopsy programs based at the Peter MacCallum Cancer Centre, WEHI, Melanoma Institute Australia, the University of Zurich and The Princess Margaret Cancer Centre, Toronto. The central theme of these projects is to use multiple samples from primary melanomas and metastases obtained at autopsy to investigate tumour evolution and the emergence of genetic heterogeneity, therapy resistance and organ metastases. A particular emphasis will be placed on lethal brain metastases. Samples will undergo whole genome sequencing (n=10-20) or whole exome sequencing (n>100), producing a unique genomic dataset. Melanoma is the third most common form of cancer in men and women and Australia has the highest rates of melanoma in the world. Tumour evolution and the emergence of genetic heterogeneity and therapy resistance are major obstacles to successful melanoma treatments. This unique collection will provide valuable insight into melanoma evolution and therapy, which will be critical in predicting patient prognosis and improving outcomes. Access to de-identified somatic variant calls (single nucleotide, copy number and rearrangements) will be made freely available. Access to de-identified raw data will require approval. This will provide vital data for melanoma researchers and will enable bioinformatics groups to develop novel algorithms for understanding tumour genomes.